JCR Pharma Sets 2026 Filing, 2027 Launch Target for DMD Drug Givinostat in Japan
JCR Pharmaceuticals will file for Japanese approval of givinostat, already sold for Duchenne muscular dystrophy in the US, EU and UK, using foreign trial data instead of a fresh domestic pivotal study, with a 2027 launch in view after talks with Japan's drug regulator.